EGFR and breast carcinoma: Lapatinib, a reversible tyrosine kinase inhibitor (TKI) to HER2 and Epidermal Growth Factor Receptor (EGFR), is currently approved for use in HER2-positive breast cancer patients after progression on a trastuzumab containing regimen [10].